Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05785845 · ClinicalTrials.gov registry record · NA

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

A NA study of Non-Small Cell Lung Cancer and Early Stage Non-Small Cell Lung Cancer, sponsored by Washington University School of Medicine.

Active
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT05785845: Active NA study of Non-Small Cell Lung Cancer and Early Stage Non-Small Cell Lung Cancer, sponsored by Washington University School of Medicine.

NCT05785845 is a NA study of Non-Small Cell Lung Cancer and Early Stage Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 17 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05785845, a NA study of Non-Small Cell Lung Cancer and Early Stage Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Washington University School of Medicine.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the impact of CT-guided adaptive stereotactic radiotherapy (CT-STAR) to central and ultra-central early-stage non-small cell lung cancers on grade 3 or greater toxicity. Online adaptive radiation therapy was until recently only done clinically on an integrated MRI-guided system, but recently, Varian Medical Systems has created a CT-guided radiotherapy machine capable of online adaptive radiotherapy (ETHOS). The vast majority of stereotactic body radiotherapy (SBRT) for early-stage lung cancers is performed on a CT-guided machine rather than an MRI-guided machine, necessitating the evaluation of adaptive radiotherapy using ETHOS in this population. Historically, the non-adaptive, stereotactic treatment of central and ultra-central thoracic disease has been associated with unacceptable rates of grade 3+ toxicity. This has resulted in widespread adoption of a hypofractionated, less ablative 8-15 day treatment courses, with a baseline, one-year grade 3+ toxicity rate of 20%. Use of CT-STAR with daily, CT-guided plan adaptation to carefully spare adjacent organs-at-risk (OAR) in this setting may enable safe delivery of a shorter (5 fraction) and more ablative radiotherapy course.

Primary Outcome

-Toxicity graded per CTCAE version 5.

Interventions

  • RADIATION Computed tomography-guided stereotactic adaptive radiotherapy
  • DEVICE ETHOS

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2023-04-10
Est. Completion 2026-07-28
Phase NA

What the registry record for NCT05785845 still lists

NCT05785845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Computed tomography-guided stereotactic adaptive radiotherapy is the first listed.

NCT05785845 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT05785845 about?

NCT05785845 is a clinical study titled "Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer". This study will evaluate the impact of CT-guided adaptive stereotactic radiotherapy (CT-STAR) to central and ultra-central early-stage non-small cell lung cancers on grade 3 or greater toxicity. Online adaptive radiation therapy was until recently only done clinically on an integrated MRI-guided sys...

What is the current status of trial NCT05785845?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 17 participants. The study started on 2023-04-10. Estimated completion is 2026-07-28.

What conditions does trial NCT05785845 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Early Stage Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT05785845?

The interventions under investigation include: Computed tomography-guided stereotactic adaptive radiotherapy (RADIATION), ETHOS (DEVICE).

Who is sponsoring clinical trial NCT05785845?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05785845 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05785845's enrollment target sits among peer trials

17 428th of 454 higher than 27 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05785845, the US trial registry maintained by the National Library of Medicine. NCT05785845 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.